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Abstract
11β-Hydroxysteroid dehydrogenase type 2 (11βHSD2) is a short-chain dehydrogenase/reductase (SDR)
responsible for inactivating cortisol and preventing its binding to the mineralocorticoid receptor (MR).
Nonfunctional mutations in HSD11B2, the gene encoding 11βHSD2, cause the hypertensive syndrome
of apparent mineralocorticoid excess (AME). Like other such Mendelian disorders, AME is rare but has
nevertheless helped to illuminate principles fundamental to the regulation of blood pressure.
Furthermore, polymorphisms in HSD11B2 have been associated with salt sensitivity, a major risk factor
for cardiovascular mortality. It is therefore highly likely that sequence variation in HSD11B2, having
subtle functional ramifications, will affect blood pressure in the wider population. In this study, a three-
dimensional homology model of 11βHSD2 was created and used to hypothesize the functional
consequences in terms of protein structure of published mutations in HSD11B2. This approach
underscored the strong genotype-phenotype correlation of AME: severe forms of the disease, associated
with little in vivo enzyme activity, arise from mutations occurring in invariant alignment positions.
These were predicted to exert gross structural changes in the protein. In contrast, those mutations
causing a mild clinical phenotype were in less conserved regions of the protein that were predicted to be
relatively more tolerant to substitution. Finally, a number of pathogenic mutations are shown to be
associated with regions predicted to participate in dimer formation, and in protein stabilization, which
may therefore suggest molecular mechanisms of disease.
Keywords: apparent mineralocorticoid excess, homology modeling
THE MINERALOCORTICOID RECEPTOR (MR) has equal affinity for aldosterone and the main glucocorticoid,
cortisol (5). Cortisol circulates at 100–1,000 times higher concentration than aldosterone, and
specificity of MR in mineralocorticoid target tissues is due to colocalization of the receptor with the
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enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) (24). 11βHSD2 catalyzes the conversion of
the MR ligand cortisol to cortisone, which does not activate the receptor (see Fig. 1).
11βHSD2 has an important role in the physiological regulation of blood pressure, and loss-of-function
mutations in the encoding gene, HSD11B2, cause the syndrome of apparent mineralocorticoid excess
(AME; OMIM +218030), characterized by hypokalemia and low-renin hypertension (14, 21, 45, 49).
Fewer than 100 cases of AME, mostly children, have been reported worldwide. However, it is highly
likely that the severity of AME precludes an accurate estimation of prevalence. AME causes a failure to
thrive, and in a mouse model of the disease 50% of individuals die within 48 h of birth because of
complications associated with severe potassium wasting (34). A mild form of AME (OMIM 207765) has
been described in which enzyme activity is reduced, rather than ablated (38, 61, 66). However, the
strong correlation between disease phenotype and underlying enzyme activity militates against
subclassification into distinct variants and indicates that AME is a continuum disorder. Indeed,
polymorphisms in HSD11B2 have positive associations with either blood pressure per se or salt
sensitivity of blood pressure (1, 2, 13, 40, 43, 54, 65), and as such it is an attractive candidate gene for
hypertension in the general population. Given that subtle changes in coding and noncoding regions
may well contribute to an elevation of blood pressure, predicting the functional ramifications of
sequence variation is of considerable interest.
11βHSD2 is a 405-amino acid, 42-kDa (11, 12) member of the “short-chain dehydrogenase/reductase”
(SDR) family of NAD- or NADP-dependent oxidoreductases, a large protein family with 73 documented
members in the human genome (see Ref. 10 for review). SDRs are diverse, including epimerases and
dehydratases (53), and pairwise identities between family members are low. Since there are no high-
resolution experimentally determined three-dimensional structures for 11βHSD2, a structure-based
analysis necessitates generation of a homology model. The closest relative to 11βHSD2 is 17βHSD2
(38% identity over 387 alignable residues, E value = 2e-63), which also lacks a solved structure. A
model previously generated for 17βHSD2 was used as the basis for a model employed to investigate
cofactor binding in 11βHSD2 (4). Cofactor preference of 11βHSD2 was thereby shown to be due
primarily to Glu115, which provided steric and coulombic repulsion with the adenosine ribose
phosphate group. Asp91 was also implicated and shown to provide important stabilizing interactions
with other residues.
17βHSD1, a more distant relative of 11βHSD2 than 17βHSD2 (26% identity over 346 alignable
residues, E value of 9e-16), which does have a resolved structure, was used in conjunction with a model
of glucose dehydrogenase to hypothesize a structure for 11βHSD2 (12). This model was used to examine
the functional impact of an Asp to Asn mutation in 11βHSD2 at residue 223. These models were either
unavailable or unsuitable for the present study because of low definition outside the authors' region of
interest. We have generated a new predicted structure of 11βHSD2 based on 17βHSD1 in order to
interpret the functional consequences of AME-associated mutations in HSD11B2.
MATERIALS AND METHODS
Extraction of Known 11βHSD2 Mutations
A manual search of the literature identified all currently known natural and engineered mutations in
11βHSD2 and correlated them, where possible, with enzyme activity.
Interpretation of a Multiple Sequence Alignment
The multiple sequence alignment for Ensembl (30) protein family ENSFM00500000270244,
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containing 11βHSD2s and the paralogous 17βHSD2s, was downloaded and filtered down to nine
species: human, chimpanzee, mouse, rat, zebra fish, frog, cow, pig, and chicken. This alignment
provides a resource of information on the structural and functional constraints experienced by
equivalent positions between protein structures. Gene duplication events produce paralogous groups of
genes with related but distinct functions—caused by different selection pressures on function—but with
similar structural constraints. Assuming sufficient substitution has occurred since the common ancestor
of a pair of sequences, positions significant for protein structure or function are expected to exhibit
global or clade-specific conservation. Patterns of substitution between the orthologs of human 11βHSD2
were examined and compared with those of the 17βHSD2s.
Fold Recognition, Template Selection, and Target-Template Alignment
A fold recognition search of the human 11βHSD2 sequence by PHYRE (32) expectedly revealed that the
sequence was compatible with an oxidoreductase/NAD(P)-binding/Rossmann-fold domain; all of the
top 10 “hits” had very high confidence scores (E value < 10 ; estimated precision = 100%). The
sequence of human 11βHSD2 was input to BLASTP (3), applied against the Protein Data Bank (PDB)
(8), identifying a 17βHSD1 structure [PDB ID: 1JTV; 1.54  (25)] as the best template, with an E value
of 9e-16. The PROMALS3D server (39) was employed to produce an alignment of 11βHSD2 against the
template structure and other related sequences. From this, manual refinements were made to the
target-template alignment to avoid placement of gaps in locations that would disrupt large secondary
structure elements predicted from sequence or template homology (in many cases equivalent; see Fig. 3
).
Incorporation of Ligands
Ligands were incorporated into the template structure with PyMol (18). The SDR structure is well
conserved in the cofactor-binding domain, although there are cofactor-dependent variations. NAD was
added via superposition of xylitol dehydrogenase [PDB ID: 1ZEM (19)], which was crystallized with
NAD. Models were created incorporating the entire xylitol dehydrogenase cofactor-binding domain as
an additional template for modeling, but this produced inferior models. In addition, the testosterone
ligand in 1JTV was replaced with cortisol, obtained from the PDB and structurally overlaid with
testosterone. It was observed (25) that androgens such as testosterone (C19 steroids) bound to
17βHSD1 in the opposite orientation when compared with estrogens (C18). Rotating cortisol into an
estrogen-like orientation produced a clash with the predicted cofactor position, so an androgen
orientation was assumed. Given the substantial differences between 11βHSD2 and 17βHSD1 in this
region, a different placement is possible.
Modeling
Modeling was performed using Modeller 9v6 (55). The dimer interface was inherited from the modified
template structure. NAD was modeled explicitly by Modeller, while cortisol was considered as a rigid
body with minimal participation in the modeling process. Fifty models were generated, from which the
best was selected on the basis of packing and stereochemical assessments. Modeller's internal “DOPE”
score (56) was employed to rank models, and from among the top-scoring 50% models assessments
were made for stereochemistry (dihedral statistics) in the form of Ramachandran plots (41), model
validity assessed with ProQ (63) and Verify3D (42), and coarse packing quality evaluated with WHAT
IF (62). Additional analysis of packing and stereochemistry was carried out by use of RAMPAGE (41).
Refinement
−40
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Where the model did not fit with known important regions in the loops that bind NAD, refinements
were made to the starting alignment and the model was recalculated.
Analysis
Known pathogenic mutations of 11βHSD2 were mapped onto the model structure and interpreted in
the context of existing structure-function data. Secondary structures for template and model were
defined by use of Stride (23). Atoms were defined as “in contact” if their predicted separation was <0.5
 plus their respective van der Waals radii. Polar contacts were identified by use of routines from
PyMol. (Caveat lector: Inaccuracies are likely, particularly at the COOH-terminal end of the molecule
where similarity with the template is low.)
RESULTS AND DISCUSSION
Comparison with Related Sequences
NADP-dependent 11βHSD1, despite substrate similarity, shares only 23% identity with NAD-dependent
11βHSD2 over 302 alignable residues and has a predicted single membrane helix (compared to 3 in
11βHSD2), producing an endoplasmic reticulum-luminal localization of the catalytic domains, opposite
to 11βHSD2's cytoplasmic orientation (51).
A multiple sequence alignment was constructed in order to examine positional constraints on
substitution in 11βHSD2. Because of the inherent diversity of the SDR family, producing a reliable
alignment can be difficult. To ensure as accurate an alignment as possible a group of 11βHSD2
orthologs was compared with a closely related paralogous group of orthologs, the 17βHSD2s. While
17βHSD2s also lack a solved crystal structure, the high sequence similarity to 11βHSD2s (and resultant
high-reliability alignment) ensures that conservation-based inferences in the following discussion are
reliable. The alignment, shown in Fig. 2, forms the basis of subsequent discussion.
Prediction of 11βHSD2 Protein Structure
The closest homologue in the PDB to 11βHSD2 was human 17βHSD1, available under PDB identifiers
1IOL (7) and 1JTV (25) and a close match with an E value of 9e-16. Although a previous model based
on this template (12) was kindly made available to us, the substrate binding residues were outside the
original region of interest and were therefore not well defined, so we have generated a new model.
The resolution of 1JTV (1.54 ) was higher than that of 1IOL (2.30 ), and hence it was employed as
the primary template. However, this structure was incomplete, lacking solved residues after Thr190
(1JTV numbering) that is present in the 1IOL structure. This fragment from 1IOL was therefore
included when modeling this region.
11βHSD2 is believed to form dimers (28), so the existing dimeric quaternary structure of the template's
biological assembly was deemed suitable for modeling. Functionally, dimer formation in 11βHSD2 may
be necessary for enzyme activity, and its disruption may be responsible for a lack of activity in
homogenates (50). This fits well with observations in 17βHSD1 (employed here as template), in which
the active unit is a dimer (35), but seems to be in contradiction to other experiments that suggested an
inhibitory role for dimer formation in 11βHSD2 (28). Whatever the mechanisms involved, dimerization
seems to be important for function, and its disruption may therefore lead to pathological consequences.
Figure 3 shows the sequence alignment of 11βHSD2 with those residues of the template sequence
present in the solved structure (residues 81–368), a JPred (15)-predicted secondary structure for
11βHSD2, and the Stride-derived (23) secondary structures of 17βHSD1. The probable NH -terminal
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Quality assessment of model structure.
Variable phenotypic impact of mutation.
helices are evident in an unaligned region. The high content of conformationally important proline and
glycine residues in the COOH-terminal unaligned region of 11βHSD2 is indicative of disorder, which
may explain the absence of solved amino acid residues in this region for homologous structures.
Examination of the model by use of a Ramachandran plot in
RAMPAGE (41) showed that 93% of modeled main chain positions have “favored” conformations,
with only 2% retaining incorrect geometry. This is acceptable and indicates that the model
stereochemistry is of good quality. Similarly, the LGscore (16) and MaxSub scores for the model,
obtained from the ProQ server (63), indicated a very (3.810) or fairly good (0.393) model, respectively.
The mean three-dimensional profile score for the model derived from Verify3D (42), which measures
the compatibility of a sequence with a proposed structure, was 0.33, comparing favorably with the
template's score of 0.51. Below-zero smoothed scores, indicating problematic modeling, occurred only
at, or adjacent to, regions lacking template-derived constraints (residues 274–290 and 106–107).
Poor packing of amino acids is often an indication of poor prediction of amino acid side chain
orientation, and this was assessed with the coarse packing quality metric available in WHAT IF (62).
This produced an average overall quality control score of −1.067. To place this in context, incorrect
models give scores of less than −3.0, lower-quality models less than −2.0; and the average quality of
235 highly refined X-ray structures was −0.59 (±0.4) (62). Only 10 or 9 residues of 288 modeled
residues, in chains A and B, respectively, fall below the −5.00 threshold that would indicate significant
problems in packing. These occur almost exclusively in loop regions of the model where homology
between query and template is especially low.
Figure 4 shows the proposed placement of NAD and cortisol ligands within the model, with two chains
arranged in a dimeric fashion with reference to the PQS-derived (29) dimer structure of 17βHSD1, and
highlights regions of low confidence in the model. L114 of chain A exhibits poor packing, but being
located in the ligand or cofactor binding sites this may relate to the structural constraints specific to
ligand binding and hence may not necessarily indicate poor modeling. Of the remaining problematic
regions, many occur in loops between secondary structure elements, which are poorly modeled because
of low identity with the template. In particular, the 274–290 loop region highlighted as problematic by
Verify3D contains a large insertion relative to the template.
Documented AME-Associated 11βHSD2 Mutations
Table 1 presents all known nonsynonymous mutations in 11βHSD2, which result in AME or
hypertension. R337C was the first such discovery (68), found in three homozygous siblings with AME,
and was followed quickly by several more homozygous mutations from multiple families (67).
Compound heterozygotes (R208H,R337H+ΔY338) with AME were later identified (33, 46), and
reduced 11βHSD2 activity in patients was demonstrated for both homozygotes and compound
heterozygotes (R213C, Y232S, truncation) (46). In addition to point changes in protein sequence,
mutations leading to truncated proteins were also found in two siblings with AME and a stillbirth (59).
Not all mutations in the HSD11B2 gene lead to full-blown AME
pathology and/or inactive enzyme. A patient homozygous for P227L showed only modestly (42%)
reduced cortisol to cortisone conversion (66). The R279C mutation (38) also had mild biochemical
phenotype—albeit with typical AME presentation. Mutations S180F, A237V, and A328V were all shown
to have significant levels of partial activity when expressed in whole cells, while L179R and R208H were
inactive (47). Defects in the enzyme activity of 11βHSD2 or perturbed cortisol metabolism has been
demonstrated in the heterozygous parents of AME patients with homozygous 11βHSD2 mutations (44,
2
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Impact of mutation on stability.
Noncoding mutations.
Mutated positions proximal to ligand or cofactor binding regions.
Mutated positions with possible implications for protein stability.
58), which sometimes lead to mild, late-onset hypertension. In particular, this has been demonstrated
for A328V (37) and ΔL114+E115 (52).
Reduced protein stability rather than reduced catalysis was shown to be
the cause of reduced 11βHSD2 activity for positions 335–339 (6) (associated with rapid protein
degradation at the proteasome) and for COOH-terminal truncated forms (50).
A number of other genetic determinants of often milder disease symptoms have
been found associated with HSD11B2, including untranslated region (UTR) elements (36) and
polymorphisms (1, 9, 13, 57, 65), but are not pertinent to the present structural discussion.
Structural and Functional Implications of 11βHSD2 Mutations
Known pathogenic mutations of 11βHSD2 were interpreted on the basis of their structural context in
the 11βHSD2 model, conservation with related sequences, and existing functional knowledge from the
available literature. Figure 5 shows placement of these mutations in the model structure and highlights
Arg279 (in white). Arg279 was indicated as problematic for sequence-structure compatibility by
Verify3D (42) and for packing by WHAT IF (62), probably because of location in a region of low
template homology close to an insertion in 11βHSD2 relative to 17βHSD1.
Figure 6 shows those pathogenic
mutations occurring close to the ligand or cofactor binding regions, and whose mutation is likely to
impact directly on enzyme activity. Of the residues shown, Tyr232, Lys236, Leu114, Glu115, and Asp91
have well-documented impacts on enzyme function and/or cofactor binding (4, 48, 52). Leu114 makes
hydrophobic contacts with the NAD cofactor, a role fulfilled by an arginine residue in the template
structure, which also provides a positive charge to facilitate binding of the phosphate in NADP. Glu115
has a key role in defining substrate specificity for NAD over NADP (4), most probably via coulombic
repulsion. Asp91 may be critical for stabilizing the conformations of a number of residues important for
cofactor binding (4). The side chain of Tyr226 (36) lies within 3  of the predicted position of the
substrate, so mutation is likely to disrupt ligand binding. Pro227 mutations (P227L, P227N) probably
have related effects, since P227 creates a “kink” important to maintain the structural positioning of
Tyr226.
Mutations that do not directly affect
substrate or cofactor binding can disrupt protein function. For example, the R337C mutation reduces
stability of 11βHSD2 (20), and variants lacking a nonconserved COOH-terminal peptide have increased
protein turnover (50). Similarly, experiments in heterologous expression systems have suggested that
the S180F, A237V, and A328V mutants have reduced stability (47). Protein destabilization has been
shown to be the root cause of reduced enzyme activity for a number of pathogenic and artificial
mutations in the residue 335–339 range (6). R337C and Y338H were completely inactive, as were all
mutants of Tyr338. Subcellular location suggestive of misfolding was shown for Y338H, as well as
recovery of activity in conditions favoring increased stability.
Figure 7 shows the predicted positions in structure of the known stability-associated residues of
11βHSD2. The 335–339 cluster occurs in proximity to a COOH-terminal region (347–368) of the
second chain of the model, assigned a helix-loop-helix arrangement by reference to the 17βHSD1
template as part of the dimer interface (Fig. 7, bottom left). The spatial arrangement of interactions
between numerous disease-associated positions is reproduced from those of the 17βHSD1 template, and
is likely a core structural feature of this protein family. The hydroxyl group of Y338 makes a hydrogen
bond with the main chain of R335, and its bulky ring system lies in close proximity to A328, supporting
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Other mutated positions occurring at predicted dimer interface.
a hydrophobic interaction. In the process, a kink is introduced (also present in the template structure)
that causes arginines 335–337 to project outward from the loop, toward one of the long supporting
helices of the structure, and the other dimer. Tyrosine is the only amino acid that has the hydrophobic
bulk to generate this kink together with a hydrogen bonding potential, which may explain the total
inactivation observed when this position is mutated. The pathogenic and functional impact of the
relatively conservative A328V mutation (37) is consistent with a core structural context and associated
tight packing for Ala328. Arg213 (46), located in a β-strand of the central β-sheet of the structure,
seems to anchor this loop via a number of hydrogen bonds that would be disrupted in R213C.
Differences with the template make inferences more tentative for other positions in this region. The
equivalent residue to Arg337 in the template, Arg252 (see Fig. 3), is involved in intrachain polar
interactions with the side chains of Glu163 and Glu167 and main chain atoms of the other subunit at
Pro270. In the model there is a predicted deletion relative to the template where a Pro270-equivalent
residue would otherwise be. This shortens the interhelix loop, and Glu163 and Glu167 are substituted
with Ala240 and Asp244, respectively, seemingly precluding interaction with Arg337, which may
instead form interchain contacts (see below). Asp244 (mutated in D244N) is predicted to participate in
an ionic interaction with residue Arg336 (template L251) that lies within the aforementioned positively
charged cluster (residues 335–339), while the main chain of Ala240 makes an H-bond with the side
chain of Asp244.
D223Q causes impaired cofactor and ligand binding (12), and D223 is suggested to hydrogen bond to
Gln261 in the β-strand adjacent to that containing Arg337. R359W lies in the speculative helix-loop-
helix region of the structure COOH terminus close to the 335–339 cluster and may participate in
interchain interactions. A requirement for such interactions may be the cause of a preponderance of
polar residues among 11βHSD2 sequences at this position (Fig. 2, column 378), in contrast to
17βHSD2s. Mutations L376P and R374Term occur close to the COOH terminus, with potential impact
on stability as with COOH-terminal truncated forms (50), similarly for a frameshift mutation from
position 356 (67).
A final mutation with probable structural significance, but distant from the above-discussed region, is
Leu250 [associated with the L250R (17) and L250P (67) mutations], absolutely conserved between all
the 11βHSD2s and 17βHSD2s in Fig. 2 (column 263). Leu250 projects away from the dimer interface
into a highly hydrophobic environment, suggesting a position of core structural significance and
therefore likely to produce disrupted structures in mutant forms.
Potential interchain contacts form another
set of known pathogenic mutations in 11βHSD2 (Fig. 8), some of which overlap with the stability-
associated set. S180F (template Leu102), R186C (template Ala108), R208H (template Ly130), and
R337C (template Arg252) all occur at positions associated with predicted hydrogen bonds that may be
disrupted in mutant proteins. Ser180 is predicted to participate in an interchain hydrogen bond
involving its main chain with Lys201, analogous to a Leu102-Gln123 bond in the template. The side
chain of Ser180 projects intrachain, and the increase in bulk of S180F is likely to displace this region
and disrupt interaction—in addition to other structural ramifications. A237V (template Val332) and
L251S (template Leu174) are predicted to occur close to hydrophobic positions of the other chain, which
might disrupt the dimer interface by increasing side chain bulk (A237V) or polarity (L251S). The side
chain of Tyr299 [deleted in 1 case of AME (39)] occurs close to the interchain interface. The model
suggests an interchain hydrogen bond for Arg337 with Tyr353 in the less well-modeled COOH-terminal
helix-loop-helix.
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Other mutated positions in structure.
Nonpathogenic mutations.
Limitations.
The dimer interface is composed in part of a helix that supports the critically important positions
Lys236 and Tyr232, as well as Ala237, Asp244, and Leu251. Without further experiment it is impossible
to determine whether potential impact on dimerization competence or active site disruption is
responsible for the observed phenotypic effects. However, the position of many of these residues in
orientations facing the other subunit is suggestive of the former possibility.
It has been suggested (50) that the reduced activity of mutant enzymes in cell homogenates (e.g., Ref.
47; see Table 1) reflects reduced competence for oligomerization. This is in line with the majority of
research on mammalian SDRs, which suggests that interfacial structural assemblies are essential for
active site integrity and activity (26, 27), and fits with observations of pathogenic mutations close to the
dimer interface. One study (28) produced the surprising conclusion that physiologically 11βHSD2 was
inactivated on dimer formation, a result that, given the bulk of SDR research, is in need of
confirmation. If proved correct, an “active monomer” scenario would need to be reconciled with the
pathogenic nature of interfacial mutations. A possibility would be that the dimeric form acts as a
degradation-resistant reservoir of latent enzyme that on dissociation produces a transient burst of
activity before proteasomal degradation. A structural disruption impairing dimerization would then
cause constitutive rapid degradation and low-level activity. This admittedly speculative theory could be
supported by our in silico observation that AME mutations having a demonstrable effect on protein
stability lie close to the dimer interface.
Two remaining positions in the model, Arg279 [associated with
R279C (38)] and Leu179 (L179R mutation) (Fig. 9) are associated with pathogenic mutations. Arg279
lies surface-exposed in a short helix after the sixth β-strand, and was noted by WHAT IF (62) to have
problematic packing in the model, making inferences based on likely interactions difficult. However, the
pathology of Arg279 is relatively mild [mild AME/late-onset hypertension (38)], and the mutant
protein retains high partial activity in vitro, which is consistent with relatively minor
structural/functional disruptions. Leu179 is more buried and lies in a loop after short fourth helix,
exhibiting likely hydrophobic contacts with a number of positions including Leu291 and Lys280. Given
this positioning, we anticipate that L179R would disrupt packing and greatly reduce protein function,
leading to a more severe disease phenotype than R279C.
Five missense mutations in 11βHSD2, L14F, R74H, R147H, T156I, and R335H,
were initially identified in hypertensive members of the Japanese population (31). All these mutations
were found in the heterozygous state in both the hypertensive and wider normotensive population, and
are therefore likely to have more subtle effects on protein function. Leu14 and Arg74 occur in the
membrane-anchor region of the sequence and therefore are not represented in the model structure.
Arg335 is part of the 335–339 stability-associated cluster and has been previously shown to be tolerant
to conservative mutation (6). The T156I mutation is placed in a loop after the third helix, while the
relatively conservative R147H occurs in a helix. Both of these positions are distant from important
regions described so far, such as the ligand-binding and interchain regions. Heterozygosity for
relatively conservative mutations may explain their lack of severe pathogenic phenotype.
Inferences based on homology models are by their nature tentative. Disease-assignment
mutation predictions based on homology models reduce in accuracy where query-template identity is
<30% (68). This is a result of less reliable side chain interactions arising from higher main chain
position errors, an increased frequency of sequence alignment errors, and a higher number of insertions
and deletions. In addition, modeling of the “loops” without homologous template-guided restraints
becomes less accurate as loop length increases (22).
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Mutations, phenotypic severity, and conservation.
In the present study the manually curated query-template alignment shows few “long” gaps, none of
which correspond to the mutated positions of interest, that occur predominantly in regions with clear
template homology. The conservation of secondary structure elements and demonstrated favorable
scores for geometry and packing further mitigate any potential issues. The consequences of mutation
described in the present study, therefore, while still putative, are likely to be reliable.
Summary and Concluding Remarks
We have examined the available literature on known mutations in the HSD11B2 gene and assessed
them in the context of existing data and their position on a constructed three-dimensional homology
model for its encoded protein.
Mutations that cause a reduction in protein function or
expression are likely to have minor consequences relative to those that abolish enzyme activity
altogether. In general terms, nonsynonymous mutations associated with severe phenotypes are expected
to impact strongly on protein structure and/or function and be selected against. As a result, the
associated positions exhibit nonpermissive patterns of substitution when compared between
orthologous sequences.
In patients with homozygous mutations, and where the resultant mutant proteins have been
consistently shown to be inactive (R208H and L179R), the associated positions of the alignment in 
Fig. 2 (221 and 192, respectively) are invariant across the alignment. The mutations at these positions
might be expected to introduce gross structural rearrangements that abolish function. For three
nonconservative mutations for which clinical phenotype was reported as being particularly mild even in
a homozygote/compound heterozygote state, P227L (Fig. 2, pos 240), R279C (Fig. 2, pos 298), and
R359W (Fig. 2, pos 378), significantly less global conservation was present—although P227, for
example, is strongly conserved in 11βHSD2s. The positions are evidently more tolerant to substitution,
and accordingly mutations introduce more subtle changes to structure and function—which is in
agreement with their relatively peripheral posited location in structure as discussed in RESULTS.
A recurring theme in the literature of 11βHSD2 mutations is the role of protein degradation. We have
suggested that mutations previously shown to lead to more rapid turnover can be used to implicate
proximal positions in our model in a “guilt by association” approach. This degradation-associated
region is also close to the predicted dimer interface, where further AME-associated mutations are
located. Combined with observations of the impact of dimer formation on 11βHSD2 activity, this may
provide circumstantial evidence pointing to a role for dimer formation in maintaining 11βHSD2
stability.
Many recent studies have implicated reduced 11βHSD2 function in syndromes related to AME, but of
much milder phenotype, including late-onset hypertension and salt sensitivity. The recent discovery of
subtle effects on transcription via promoter polymorphism (2), and its impact on salt sensitivity, are of
particular interest. The association of mild-phenotype with heterozygous nonsynonymous, as well as
noncoding mutations and polymorphisms with disease, may have implications for a much wider section
of the population than those affected by the rare syndrome of AME. It is likely that further research will
yield a larger set of subclinical 11βHSD2 mutations that, when characterized, will yield further
information on this protein's structure and function.
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Figures and Tables
Fig. 1.
Outline of 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) mechanism. 11βHSD2 prevents activation of the
mineralocorticoid receptor (MR) by cortisol, allowing aldosterone to bind with consequent downstream effects on
transcription. ENaC, epithelial sodium channel. Figure credit: Louise Evans.
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Multiple protein sequence alignment of 11βHSD2 enzymes and their immediate neighbors, the 17βHSD2s, adapted from
the alignment for the Ensembl protein family ENSFM00500000270244. Figure prepared with Jalview (64) with
ClustalX (60) coloring option.
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Pairwise sequence alignment of human 11βHSD2 with the template used for modeling, 17βHSD1 [PDB ID: 1JTV (25),
chain A], showing only those template residues solved in the structure. Secondary structure is shown below the
alignment, derived from the sequence via the secondary structure prediction server JPred (15) and from the template
structure via Stride (23). JPred confidence scores for assignment of residues to secondary structure element are shown
for the target sequence. Red, α-helices; green, β-strands. Figure created with Jalview (64), with ClustalX coloring.
Numbers above sequences refer to alignment position, not sequence position.
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Dimeric 3-dimensional model of human 11βHSD2 based on human 17βHSD1. One monomer is shown in dark gray and
the other in white, and both are depicted in cartoon representation. NAD is shown in stick form with carbons in white,
while cortisol is shown in gray stick form. Other atoms are in standard color scheme (red, oxygen; blue, nitrogen; orange,
phosphorus). Red cartoon regions highlight portions of the model with 1 or more identified problems in modeling.
Table 1.
Summary of mutations and associated phenotypic consequences
Mutation(s) Location
Alignment
Position Reference Heterozygous/Homozygous Phenotype Pr  
Disease-associated mutations
ΔTTGGAG Exon 2 127 + 128 52 hom AME ΔL114+E115
CTG→CGG+ Exon 3 +
Exon 4
192 + 259→ 47 hom AME L179R+ fram
TCT→TTT Exon 3 193 47 hom AME S180F
CGT→TCG Exon 3 199 13, 67 hom AME R186C
CGC→TGC Exon 3 229 45 hom AME R208C
CGC→CAC/CGCTAT→CAT Exon
3/exon 5
221/356 +
357
33 het/het AME R208H/R33
CGC→CAC+ C→T Exon 3 +
intron 3
221 47 hom AME R208H+ Δex  
CGC→TGC Exon 3 226 45 hom AME R213C
GAC→AAC+ C→T Exon 4 +
intron 3
236 12 hom AME D223+ Δexo  
A→+A→T/C→T Exon 4/3′
UTR
246 36 het/het AME Y226N/–
A→G+A→T Exon 4 239 36 het LOH Y226N
CCG→CTG Exon 4 240 66 hom AME (mild) P227L
Δ9bp/Δ11bp Exon
4/exon 5
245–247 45 het/het AME Y232S,
Δ(G233+T23
TAT→TGT/CTG→CCG Exon
4/exon 5
245/397 36 het/het AME Y232C/L376
GCG→GTG/GCG→GTG Exon
4/exon 5
250/347 47 het/het AME A237V/A328
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CTC→CGC/GAC→AAC Exon
4/exon 4
263/257 17 het/het AME L250R/D244
CTCCTT→CCCTCT Exon 4 263 + 264 45, 67 hom AME L250P+L251
C→T Intron 3 45 hom AME ΔExon 4
CGC→TGC Exon 5 298 38 hom het AME
(mild) ,
LOH
R279C
AAC→AA Exon 5 17 hom AME N286 −1 fram
ΔTAC Exon 5 318 39 hom AME ΔY299
GCG→GTG Exon 5 347 37 hom/het AME LOH A328V
CGC→TGC Exon 5 398 68 hom AME R337C
CGCTAT→CAT Exon 5 356 + 357 45, 67 hom AME R337H+ΔY3
ΔCA/TAT→CTG Exon
1/exon 5
32/357 6 het/het AME Truncation a  
GAA→GTG Exon 5 375 → 67 hom AME E356 frames
CGG→TGG/G→A Exon
5/intron
3
378/– 36 het/het AME (mild) R359W/splic   
CGG→TGG Exon 5 378 36 het LOH R359W
CGA→TGA Exon 5 395 → 59 hom AME R374Term
C→T 3′ UTR 36 het LOH
Engineered mutations
245 48 Y232F
245 48 Y232S
249 48 K236R
104 48 D91N
Exon 2 128 52 E115G
Exon 2 128 52 E115K
Exon 5 396 6 R335K
354 6 R335Q
354 6 R335A
355 6 R336K
355 6 R336Q
†
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355 6 R336A
356 6 R337K
356 6 R337Q
356 6 R337A
399 6 R338F
399 6 R338A
400 6 R339F
400 6 R339A
400 6 R339H
References are cited for the discovery of each mutation and separately for the in vitro activity, where
appropriate. Activities are shown as a qualitative guide to indicate where partial enzymatic activity may
be retained by mutant proteins; however, quantitative assessments involving these values would be
unwise because of differences in experimental procedures, metrics of activity, etc.
AME, apparent mineralocorticoid excess; LOH, late-onset hypertension; UTR, untranslated region.
Multiple mutations are indicated by “/”' for compound heterozygotes, “+” for compound homozygotes.
Alignment positions relative to Fig. 2 are included for ease of cross-referencing.
Patient lacked mineralocorticoid excess.
Patients had syndrome sometimes referred to as “type II” AME, characterized by AME symptoms but
mild biochemical phenotype.
Activity measured from placental homogenate relative to control.
Fig. 5.
The model 11βHSD2 (right) compared with the template 17βHSD1 (left) with location of mutations mapped. One chain
is split by color to separate major groups of secondary structure elements. The main cofactor-binding domain is shown
in red at the NH  terminus, 2 long helices that support much of the active site are shown in green, and the COOH-
terminal region is shown in blue. Note: a short segment (amino acids 191–197) was not solved in the template [PDB ID:
1JTV (25)], seen at top left. Spheres indicate the α-carbon positions of pathogenic mutations or their equivalents in the
template—only mapped on 1 chain for clarity. White spheres indicate potential problems at these positions during
modeling (see text).
Fig. 6.
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Residues important for function or associated with apparent mineralocorticoid excess (AME) on mutation around the
substrate and cofactor binding regions. The side chains of residues involved in pathogenic mutation are shown in yellow
stick form. Dashed yellow lines indicate predicted hydrogen bonds. The location of this region with respect to the overall
model dimer is shown in the inset. Protein chains are colored as in Fig. 5 and ligands as in Fig. 4.
Fig. 7.
Residues involved in AME-associated mutations that may affect protein stability are shown labeled. The dimer is rotated
180° relative to Fig. 5. Color scheme and formatting as in previous figures.
Fig. 8.
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Residues involved in AME-associated mutations that occur at the dimer interface are indicated. The dimer is rotated
180° relative to Fig. 5. Color scheme as in previous figures.
Fig. 9.
Residues involved in AME-associated mutations that were not classified are shown. As indicated in the inset, the dimer
is shown in the same orientation as Fig. 5.
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